米托唑胺（M&B 39,565）用于结直肠癌和乳腺癌的II期研究。
Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer.
作者信息
Herait P, Rougier P, Oliveira J, Delgado F M, May-Levin F, Hayat M, Armand J P
机构信息
Department of Medicine, Institut Gustave-Roussy, Villejuif, France.
出版信息
Invest New Drugs. 1988 Dec;6(4):323-5. doi: 10.1007/BF00173652.
Twenty-two patients with advanced colorectal cancer (CRC) (12 without prior chemotherapy) and fourteen with pretreated breast cancer (BC) were given mitozolomide (MTZ), IV infusion, every six weeks. The starting dose was 90 mg/m2. When it was well-tolerated, dose escalation was done up to 100-115 mg/m2. Toxicity was mild, limited to thrombocytopenia with a median nadir of 1.27 x 10(5) (0.20-4.86). No response was observed in these patients. MTZ, according to these schedule and dosage, does not show activity in human CRC and pretreated BC.
22例晚期结直肠癌（CRC）患者（12例未接受过化疗）和14例经预处理的乳腺癌（BC）患者每六周静脉输注一次米托唑胺（MTZ）。起始剂量为90mg/m²。若耐受性良好，则将剂量增至100 - 115mg/m²。毒性轻微，仅限于血小板减少，中位最低点为1.27×10⁵（0.20 - 4.86）。这些患者未观察到反应。按照这些方案和剂量，MTZ在人类结直肠癌和经预处理的乳腺癌中未显示出活性。
Zotero 插件